Semax (ACTH Fragment Peptide)

Semax Regulatory Status: Registered Where, and Why It Matters

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Semax has been registered as a prescription medicine in the Russian Federation since the 1990s. It holds no marketing authorisation from the MHRA, EMA or FDA, has not been through Western regulatory review, and is supplied in the UK for laboratory research only.

Key facts

Registered in
Russian Federation
Registered since
1990s
MHRA status
Not authorised
EMA status
Not authorised
FDA status
Not approved
UK supply basis
Laboratory research only
Transferable?
No (authorisations are jurisdictional)

What a national registration is

A marketing authorisation is a decision by one regulator, about one product, in one jurisdiction, for defined indications, on the evidence submitted to it. It reflects that regulator's evidentiary standards and its assessment of benefit and risk for its own population. It is not a statement about a compound in the abstract, and it does not travel.

Why registration elsewhere does not change UK status

The MHRA assesses products submitted to it. A compound registered in Russia, or anywhere else, has no UK status until a UK application is made and assessed. Semax has not been through that process. Its position in the UK is therefore identical to any other unlicensed compound: it is not a medicine here, cannot be prescribed or dispensed, and is supplied for laboratory research.

Research material referenced

Semax 10mg, third-party HPLC tested

Buy Semax · £24.99

Why the difference in standards matters

Regulators differ in what evidence they require and how they weigh it, and those requirements have changed considerably over three decades. A registration granted in the 1990s on the evidence available then would not necessarily survive assessment against current standards for trial design, pre-registration and reporting. This is true generally and is not a claim specific to any one agency.

The line this site keeps

Reporting that a national regulator registered a compound for named indications is a fact about a decision. Stating or implying that the compound treats those conditions is a therapeutic claim, and under the UK framework a therapeutic claim about material supplied for research is what converts it into an unlicensed medicine. The MHRA opened investigations into UK retailers making that kind of claim in April 2026. This distinction is the reason these pages describe registrations rather than repeating indications as if they were established outcomes.

What would change the position

A UK marketing authorisation, following an application and assessment by the MHRA. Nothing else does: not registration in another country, not published literature, not length of use elsewhere.

Frequently asked questions

Does Russian registration mean it is proven?

It means one regulator assessed a submission against its own standards and granted an authorisation. Standards differ between agencies and have changed over three decades.

Could Semax be approved in the UK?

Only through an application to and assessment by the MHRA. No such process has taken place.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Semax (ACTH Fragment Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.